• Amino acid substitution at peptide binding residues of the HLA class I molecule is associated with graft versus host disease and mortality.
Introduction:
The majority of allogeneic hematopoietic cell transplantation (HCT) procedures utilize adult volunteer unrelated donors, and robust evidence supports the adverse impact of donor-recipient HLA disparity on important HCT outcomes. [1] [2] [3] [4] [5] [6] [7] In the largest analysis to date, Lee, et al reported that high resolution DNA matching at HLA-A, -B, -C, and -DRB1
(8/8 match) resulted in optimal outcomes, while single antigen-or allele-level mismatch was associated with increased hazard for acute graft versus host disease (GVHD) and an approximately 10% reduction in one year survival; multiple mismatches compounded this risk further. 3 Unfortunately, an 8/8 match cannot be found for all patients in need of transplantation. The National Marrow Donor Program (NMDP) estimates that approximately 30% of Caucasian and up to 70% of minority patients will not find an 8/8 match.
Insights into the relationship between the nature and position of HLA mismatch and its functional consequences are needed to mitigate risk for severe acute GVHD and mortality. Studies have come to divergent conclusions regarding the impact of mismatch at individual HLA loci. 3, 8 Investigators have attempted to estimate allogenicity of individual HLA class I or II donor-recipient mismatches. [9] [10] [11] Others have attempted to identify specific non-permissive donor-recipient allele combinations or specific amino acid substitutions (AAS) associated with increased risk for severe acute GVHD and treatment-related mortality, [12] [13] [14] [15] primary malignancy relapse, 16 or 100 day mortality post-HCT. 17 We proposed that AAS at peptide binding pockets or killer immunoglobulin-like receptor (KIR) binding domains would have greater impact on GVHD and mortality. We
For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From anticipated that AAS at peptide binding sites would alter antigen presentation and therefore confer greater risk for serious acute GVHD compared to AAS at other sites. In a large analysis facilitated by the Center for International Blood and Marrow Transplant
Research (CIBMTR), we aimed to (1) establish the impact of AAS at peptide binding positions 9, 99, 116, and 156, and KIR binding position 77, 18, 19 of the HLA class I molecule on HCT outcome, (2) determine whether this effect is restricted to particular HLA class I loci, and (3) examine impact of specific AAS residue pairs on HCT outcome.
Patients and Methods:

Study population
The study population included adult and pediatric patients who underwent a myeloablative or reduced intensity/non-myeloablative first unrelated bone marrow or Available DPB1 high resolution typing information was utilized in secondary analyses,
given previously reported association of HLA-DP mismatch and acute GVHD; 3,21 HLA-DQ mismatch was not considered, given insufficient evidence of such an effect. All
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Research was approved and conducted under supervision of the NMDP Institutional Review Board. This study was conducted in accordance with the Declaration of Helsinki.
Outcomes
Overall survival (OS) summarized time from HCT to death from any cause. Treatmentrelated mortality (TRM) included death in continuous remission from primary disease; events were summarized by the cumulative incidence estimate with relapse as a competing risk. Severe acute GVHD included development of grade III-IV acute GVHD according to consensus grading. 22 Chronic GVHD was reported as the cumulative incidence of limited or extensive chronic GVHD. 23 Primary malignancy relapse was summarized by cumulative incidence estimate, with death as a competing risk.
Variables tested
The main effect tested was the presence of AAS at positions 9, 77, 99, 116, and 156 among 7/8 matched donor-recipient pairs on HCT outcomes. 
Statistical methods
Descriptive statistics were utilized to summarize the characteristics of the data set. The
Chi-Square test was used to compare discrete factors between groups. The KruskalWallis test was used to compare continuous factors between groups. Probabilities for overall survival and disease-free survival were calculated using the Kaplan-Meier estimator with variance estimated by Greenwood's formula. Comparison of survival curves was made using the log-rank test. Relapse and TRM were calculated as cumulative incidence using a linear approximation to estimate the variance.
Multivariate analyses were performed using the proportional hazards model. All clinical variables were tested for the affirmation of the proportional hazards assumption, and factors violating the proportional hazards assumption were adjusted through stratification. A stepwise model building approach was utilized for the primary outcomes.
Interactions among the significant AAS variables and the clinical variables were tested.
Multivariate analysis for the amino acid mismatches was performed by treating the AAS at each position as an independent variable. A stepwise model selection procedure was adopted to identify amino acid substitution sites most associated with the outcomes, controlling for other mismatches present. Adjusted cumulative incidence curves were also generated to illustrate major study findings. 24 In the primary analysis, 7/8 mismatched donor-recipient pairs with AAS at the residue of interest (separately tested 9, 77, 99, 116, 156) were compared to 7/8 pairs without AAS at the residue of interest. In all analyses, the comparator group without AAS of interest did not include 8/8 pairs. The 8/8 pairs were only utilized in multivariate models to estimate the impact of non-HLA variables on outcome. Separate models were also constructed to examine the impact of AAS at these residues when limited to particular 
Impact of type and number of AAS on outcome, irrespective of HLA-locus
In the primary analysis, only AAS at position 116 was associated with significant increase in grade III-IV acute GVHD (HR 1.3, 95% CI 1.1-1.6, p = 0.0012), after adjustment for significant covariates including recipient age. Similar findings were observed (HR 1.3, 95% CI 1.1-1.5, p = 0.0006) when DPB1 mismatch was considered.
No other significant association was detected between AAS studied (9, 77, 99, 116, 156) and clinical outcomes.
In a separate analysis, we examined the impact of specific AAS in combination, as well as the total sum of AAS. The sum of AAS was associated with increasing hazard for TRM, with sum of 5 AAS HR 1.7, 1.2-2.5, p = 0.006. Additionally, the sum of AAS among 7/8 matched pairs was associated with grade III-IV acute GVHD (p < 0.0001). This effect was significant among those with mismatch at HLA-C (p = 0.0003), but not those with a mismatch at HLA-A (p = 0.03) or -B (p = 0.09). We could not demonstrate consistent association of combinations of AAS and any of the studied HCT outcomes.
AAS restricted to each class I HLA locus
Restricting AAS comparisons within each class I HLA locus, most significant findings were among HLA-C mismatches (table 3) No significant association was found between any of the other studied AAS and relapse.
In addition, no significant associations were detected among those with HLA-A mismatches.
AAS pair frequency and outcome
In multivariate analysis, cysteine (C) to tyrosine (Y) substitution at position 99 at HLA-C was associated with increased treatment-related mortality (HR 1.78, 95% CI 1.27-2.51, p = 0.0009), adjusted for significant covariates including disease status and recipient age.
This finding was not observed when DPB1 match was included in the model. Otherwise, we did not detect significant relationships between the tested specific AAS pairs and any of the studied HCT outcomes. We were not able to confirm the previously reported findings per Kawase, et al, 12, 16 regarding acute GVHD or malignancy relapse, although the number of pairs mismatched in these particular combinations was limited.
Comparison of the Japan Marrow Donor Program and CIBMTR/NMDP data is presented in supplemental 
Discussion:
Enormous diversity exists in the human HLA system, and thus many potential HCT candidates will not find a suitably matched unrelated donor. However, current knowledge does not readily help identify the donor that poses minimal risk for acute GVHD and mortality. Structural studies have characterized the peptide-binding groove of the HLA class I molecule, 25, 26 and have highlighted the importance of peptide binding pockets in binding and presentation of specific peptides. 27, 28 Emerging clinical outcome data suggests that AAS at key peptide-binding residues of the HLA class I molecule may result in increased risk for severe acute GVHD 12 and mortality. 17 In a large analysis, and interact with bound peptide. [28] [29] [30] Amino acid substitution at position 116 affects the steric conformation of the F pocket, 29 altering peptide binding and allorecognition. 31, 32 Thus, our HCT outcome data support the functional implications of AAS at this key residue.
We have also identified that AAS at position 99 and 116 among 7/8 pairs mismatched at HLA-C are associated with significantly increased risk for TRM. In our analysis of specific amino acid pairs and HCT outcomes, we demonstrated that cysteine (C) to tyrosine (Y) substitution at position 99 at HLA-C was associated with increased TRM.
We could not detect significant association between other amino acid pairs and outcome. AAS previously reported by Kawase, et al as important for severe acute GVHD and malignancy relapse, respectively, 12, 16 were not substantiated by our analysis. The frequency of these amino acid substitution pairs is generally lower in the NMDP/CIBMTR data set (supplemental table 1). A notable exception is Asparagine-Serine at position 77 of HLA-C; while the observed frequency is greater in our sample, we could not demonstrate the previously reported increased risk for severe acute GVHD. The effects reported by Kawase, et al may be more apparent in a more homogenous population.
A novel finding of our analysis was the association of AAS at position 9 among 7/8 pairs mismatched at HLA-B with risk for chronic GVHD. Providing potential mechanistic support for this finding, previous biologic studies have demonstrated that AAS at position 9 alters peptide binding and allorecognition. [33] [34] [35] In addition, while this association has not been previously reported at the amino acid substitution level, prior clinical outcome data has suggested the association of class I HLA, 36, 37 or specifically HLA-B allelic mismatch, 4 with risk for chronic GVHD. In contrast, other investigators have not detected an impact of HLA-B allelic disparity on risk for chronic GVHD development following HCT.
3, 11, 13 We acknowledge the following limitations of our analysis: Low numbers of observations in certain subgroups may limit power to detect significant differences; for example, HLA-C mismatch and AAS 116 have greater representation in this sample than mismatch at other HLA class I loci and other AAS positions. The overall diversity of this sample limited our analysis to only a subset of AAS pairs of sufficient frequency. Our analysis is only limited to adult volunteer unrelated donor transplantation, and we can not comment on alternative donor sources. Low numbers of observed events precluded study of the impact of AAS on engraftment failure. Finally, we acknowledge that differences in patient, disease, and transplantation characteristics may impact our results. The observed differences suggest that clinicians take patient factors such as age and disease into account when electing to utilize mismatched donors, and modify transplant practices in this setting. We have tried to address these concerns through the conduct of multivariate analyses controlling for any significant covariates but this may not fully account for such factors.
In summary, these data support that AAS at key peptide-binding residues of the HLA class I molecule is associated with severe acute GVHD and death. Donor-recipient pairs with such AAS should be avoided to optimize HCT outcomes.
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